VORAPAXAR – FIRST REPRESENTATIVE OF THE NEW CLASS OF ANTIPLATELETS


E.A. Ushkalova

Department of General and Clinical Pharmacology of Russian People’s Friendship University, Moscow
Key role in the pathogenesis of atherothrombosis belongs to platelets: therefore, antiplatelet agents is the main pharmacological group used for primary and secondary prevention of atherothrombotic complications. The article presents the review of studies on vorapaxsar, the first representative of a new class of antiplatelet agents - protease-activated receptor antagonists (PAR-1).

About the Autors


E.A. Ushkalova – MD, Prof. at the Department of General and Clinical Pharmacology Russian People’s Friendship University; e-mail: eushk@yandex.ru


Similar Articles


Бионика Медиа